Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-03

Study Completion Date

2021-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in predicting the response to bivalent HPV vaccine after whole blood stimulation

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts

NCT05761002

Human Papilloma Virus Anogenital Wart

UNKNOWN NA

Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts

NCT05326152

Intralesional Versus Intramuscular Hepatitis B Vaccine for Multiple Common Warts

COMPLETED PHASE1/PHASE2

Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

NCT04399577

Warts

COMPLETED PHASE2

Triple Antigen vs Monoantigen Immunotherapy for Warts

NCT05254561

Triple Intralesional Immunotherapy Combination in Multiple Recalcitrant Warts

COMPLETED PHASE2/PHASE3

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

NCT05291845

Warts Human Papilloma Virus

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

40 Patients and 40 controls are enrolled in the study. Participants suffer from chronic recurrent cutaneous and genital warts. Blood samples were withdrawn then whole blood cultures are prepared. Cultures are stimulated with bivalent HPVvaccine. IL-4 and IFN-γ measurement in culture supernatants by ELISA. IL-4 and IFN-γ are investigated to predict the therapeutic response to bivalent HPV vaccine immunotherapy in warts.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Warts Hand Wart, Genital

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases

Patients having multiple recurrent and recalcitrant cutaneous and genital warts

IL-4 and IFN-γ measurements

Intervention Type BIOLOGICAL

Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants

Controls

Healthy volunteers matched for age and sex

IL-4 and IFN-γ measurements

Intervention Type BIOLOGICAL

Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IL-4 and IFN-γ measurements

Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with recurrent and recalcitrant cutaneous and anogenital warts.

Exclusion Criteria

* History of allergy to the HPV vaccine
* Active viral, fungal, or bacterial infections
* Immunosuppressive diseases or drugs.
* Autoimmune diseases, or other systemic diseases, e.g., hepatic, or renal disorders, diabetes, meningitis or convulsions
* Skin allergies
* Pregnancy and lactation
* Earlier wart treatment at least one month before enrollment.

Minimum Eligible Age

36 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No